aspirus health

The Aspirus Institute is recruiting participants for clinical research that has the potential to improve future treatment options for people living with cardiovascular disease. People who have had a heart attack or stroke, or have poor circulation may be candidates for this study.

The REDEFINE 3 study will examine the safety and potential benefits of Cagrilintide and Semaglutide (CagriSema) against cardiovascular events such as heart attacks and strokes in people with cardiovascular disease. During the study, researchers will track cardiovascular events (heart attacks, strokes, heart-related deaths) and changes in weight and A1C.

Participants may be eligible if:

• Have had a stroke, heart attack, or have poor circulation (peripheral artery disease)
• be over 55 years old
• Considered to be overweight or obese (BMI>25)
• have type 2 diabetes
• Possible chronic kidney disease
• You will receive regular clinic visits and phone calls for 4 to 4.5 years, depending on the study start date.

Study sponsor Novo Nordisk expects the study to last up to four-and-a-half years and enroll 7,000 participants in the U.S. and around the world.

“We are honored to have been selected to participate in this important clinical trial that translates the latest research findings into medical advances,” said interventional cardiologist German Larraín, M.D., principal investigator of the Aspirus study. Ta. “Research participants will know that they are helping others by contributing to this important research.”

All patients enrolled in the REDEFINE 3 study will be closely followed for up to 4.5 years. There are no costs associated with participation, and patients will be reimbursed for all study-related visits.

For more information about the REDEFINE 3 study, visit aspirus.org/redefine3 or call Aspirus Research Institute at 715.847.2273.